• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Bausch + Lomb (BLCO) Gains Clinical Backing As Investors Ask If The Valuation Case Holds

    Simply Wall St·09/05/2026 14:23:39
    Listen to the news

    Bausch + Lomb (BLCO) is back in focus after new peer reviewed research reported strong real world outcomes and no serious safety issues for its enVista Aspire and Aspire toric intraocular lenses used in cataract surgery.

    The new intraocular lens results land at a time when Bausch + Lomb’s share price has gained momentum, with a 7.64% 1 month share price return, a 16.69% 3 month share price return and a 20.19% 1 year total shareholder return. This points to improving sentiment around growth prospects and perceived risk.

    Scan how Bausch + Lomb compares with other eye care and medical stocks showing strong price momentum and fundamentals using our curated list of solid balance sheet and fundamentals (52 results)

    After that kind of move and fresh clinical support for key products, the question for Bausch + Lomb investors is simple: Does the current valuation still leave enough upside to justify the risks from here?

    Most Popular Narrative: 54% Undervalued

    The most followed valuation narrative for Bausch + Lomb puts fair value at $39.23 per share, compared with the latest close at $18.04. That gap is driving a very different conversation compared with the modest upside implied by traditional analyst targets.

    After reviewing historical filings, industry norms, and comparable companies:

    A. This delay is unprecedented for this company.

    There is no prior instance of an AGM result blackout of this length.

    B. This delay is highly unusual for any public company.

    AGM results are procedural, routine, and expected.

    C. The lack of communication increases governance risk.

    Shareholders cannot assess leadership legitimacy without vote results.

    D. The silence itself becomes material.

    When a company withholds information that is normally disclosed, the absence of disclosure becomes a signal.

    Read the complete narrative.

    This narrative does not hinge on small tweaks to growth inputs. It leans on a clear profit margin profile, a detailed revenue trajectory and a valuation multiple that assumes Bausch + Lomb can support those economics over time.

    Result: Fair Value of $39.23 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors still need to weigh governance concerns around the AGM disclosure gap, as well as the fact that Bausch + Lomb currently reports a net loss of $171 million.

    Find out about the key risks to this Bausch + Lomb narrative.

    Next Steps

    If this mix of risks and rewards around Bausch + Lomb leaves you unsure, move quickly and check the underlying data for yourself. To see how other investors are weighing both sides, review the 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Bausch + Lomb?

    If the Bausch + Lomb story has your attention, do not stop there. Broaden your watchlist with other ideas that match your risk comfort and return goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.